Skip to main content
Monday, August 17, 2026
BTC $64,300 ▲ 1.50%
GOKHSHTEIN.
Live WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
More SectionsDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
Menu
NewsLive WirePoliticsWorldMarketsDigital AssetsTechnologySports
FranchisesThe BriefThe Big ReadThe BreakdownCrypto Culture
MoreDeFi & On-ChainU.S. EquitiesMacro & RatesResearch
Subscribe
LIVE
BTC$64,300up+1.50%ETH$1,910up+1.20%SOL$75.98up+0.60%XRP$1.00up+0.10%LINK$9.51up+1.90%ADA$0.175down−1.50%S&P 5007,758down−0.35%Nasdaq26,655down−0.28%Dow53,503down−0.43%RUT3,061down−0.24%TNX4.71%up+0.34%TYX5.29%up+0.57%FVX4.37%up+0.11%IRX3.70%up+0.00%VIX15.24up+6.95%GOLD$4,479.90up+0.96%SILVER$66.45up+2.06%OIL$83.44up+1.26%DXY99.51down−0.16%NVDA$225.99up+0.37%AAPL$304.15down−0.58%TSLA$339.32down−0.86%META$567.30down−3.82%MSFT$479.51down−3.21%AMZN$258.87down−1.44%GOOGL$343.47down−0.70%Fear & Greed31 — FearBTC$64,300up+1.50%ETH$1,910up+1.20%SOL$75.98up+0.60%XRP$1.00up+0.10%LINK$9.51up+1.90%ADA$0.175down−1.50%S&P 5007,758down−0.35%Nasdaq26,655down−0.28%Dow53,503down−0.43%RUT3,061down−0.24%TNX4.71%up+0.34%TYX5.29%up+0.57%FVX4.37%up+0.11%IRX3.70%up+0.00%VIX15.24up+6.95%GOLD$4,479.90up+0.96%SILVER$66.45up+2.06%OIL$83.44up+1.26%DXY99.51down−0.16%NVDA$225.99up+0.37%AAPL$304.15down−0.58%TSLA$339.32down−0.86%META$567.30down−3.82%MSFT$479.51down−3.21%AMZN$258.87down−1.44%GOOGL$343.47down−0.70%Fear & Greed31 — Fear
GOKHSHTEIN.
Media · Est. 2019
The front page of everything. Breaking news and sharp analysis across politics, markets, crypto, technology, and sports — with live market data built in.
Markets
Market OverviewDigital AssetsU.S. EquitiesMacro & RatesResearch
Editorial
Politics & PolicyTechnologySports BusinessResearch
Terminal
GMarketsGo PRO
Company
AboutContactEditorial StandardsCorrectionsAdvertiseSubscribe
Legal
Privacy PolicyTerms of ServiceDisclosures
© 2026 Gokhshtein Media. All rights reserved.
PrivacyTermsDisclosures
Tag

liquid biopsy

1 article

Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
U.S. Equities2h ago
Jefferies Initiates Freenome With Buy, Sees 47% Upside in Cancer Screening
Jefferies set a $17 price target on Freenome (FRNM), trading at $11.56, citing the company's cancer screening potential as the core catalyst